(PageOne) – COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers.
The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
To view the full announcement, including downloadable images, bios, and more, click here.
Goal is to bring a much needed COVID-19 vaccine to emerging and developing nations
Agreement establishes integrated logistics to enable efficient worldwide distribution of COVAXX’s COVID-19 vaccine
Aim is to distribute up to a billion doses of the COVAXX synthetic vaccine worldwide in 2021